Corona outbreak: EU Commission approves Moderna vaccine

The next corona vaccine may be distributed in Europe. The commission gave the green light for the Moderna preparation. The European Medicines Agency had previously issued a positive recommendation.

As a second corona vaccine, the drug from the US manufacturer Moderna is now also approved in the European Union. The EU Commission decided on Wednesday on the recommendation of the drug authority Ema, as Commission head Ursula von der Leyen announced on Twitter.

The Committee for Medicinal Products for Human Use (CHMP) at Ema had previously recommended conditional approval of the product. The United States had issued an emergency approval for the Moderna vaccine before Christmas. It was also approved in Canada and Israel. After the funding from Biontech and Pfizer, it is the second Covid-19 vaccine approved in the European Union.

In contrast to the vaccine from Biontech, the Moderna active ingredient does not need ultra-cold storage and could therefore be delivered more easily. Hundreds of thousands of EU citizens have now been vaccinated with the Biontech vaccine since it was approved on December 21. Due to the bumpy start of the vaccination campaign, however, there had been criticism as to why no more had been ordered. So far, the EU has secured 300 million doses of the Biontech vaccine.

50 million vaccination doses secured

The European Union initially ordered 80 million cans from Moderna, with the option to purchase a further 80 million cans. Germany expects to receive at least 1.5 million doses of it in the first few weeks. In total, Germany has secured 50 million vaccine doses from this manufacturer via the EU. At the beginning of the week, Moderna raised its production forecast for this year and now expects to be able to produce at least 600 million cans instead of 500 million. Moderna continues to invest and hire additional staff to potentially manufacture up to a billion cans.

The company, founded in 2010, started the first corona vaccine study in the USA in the spring. According to the final analysis of the approval-relevant study, the effectiveness of the Moderna vaccine is a good 94 percent. Biontech and Pfizer had estimated the effectiveness of their vaccine at 95 percent. Both vaccines are based on a new technology, the so-called messenger RNA (mRNA), which is supposed to convey information to human cells about the production of proteins and thus about the fight against pathogens.

Leave a Comment